Novartis to Collaborate With Relation to Discover New Atopic Disease Targets
MT Newswires Live
Dec 09
Novartis (NVS) has entered into a multi-program strategic partnership with Relation to discover and advance new drug targets for atopic diseases, Relation said Tuesday.
Under the deal terms, Relation will receive $55 million upfront through a combination of payments, equity, and R&D funding, and could earn up to $1.7 billion in milestone payments plus tiered royalties on future product sales.
The collaboration will combine Novartis's immuno-dermatology expertise with Relation's AI-driven drug discovery platform and human data capabilities to identify and validate potential first-in-class targets linked to immune dysregulation, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.